Whole-exome sequencing reveals differences between nail apparatus melanoma and acral melanoma To the Editor: Nail apparatus melanoma (NAM) is considered a subtype of acral melanoma (AM). A study in Korea reported that 50% of melanomas in Koreans were AM. 1 AM and cutaneous melanoma are considered distinct on the basis of genetic evidence; AM typically has a low single-nucleotide variant (SNV) burden, high numbers of focal amplifications, and frequent TERT aberrations compared Macroscopic analysis of hair follicles isolated from follicular units is more definitive after methylene blue staining. A, Hair follicle in late catagen stage, with the epithelial strand (arrow) clearly visible after methylene blue (0.02%) staining. B, Nonstained hair follicle that cannot be clearly identified under the stereomicroscope as either late catagen or telogen, but after methylene blue staining (C), the small remaining epithelial strand (dotted-line) allows us to identify it as late catagen. D, Ki67 staining and TUNEL confirms this strand is a late catagen hair follicle, with the presence of several apoptotic, TUNEL positive cells (arrowheads). TUNEL, Terminal deoxynucleotidyl transferase dUTP nick-end labeling. with common melanomas.
2 A significant number of AMs do not carry BRAF-activating, NRAS-activating, or KIT-activating mutations. 3 A recent study in Korea revealed alterations of only 6.4% of BRAF, 4.3% of NRAS, and 8.5% of KIT genes in Korean patients with AM. 1 In this study, AM and NAM samples were obtained from 6 Korean patients. Four formalin-fixed, paraffin-embedded NAMs and paired normal skin tissues were obtained from patients who underwent Ray amputation. Two frozen AM tissue samples and paired blood samples were obtained from patients who underwent wide excision biopsy.
To find genomic differences between AMs and NAMs, melanomas with matched normal samples were analyzed by whole-exome sequencing. Mean sequencing depth coverage was x117.9. Whole-exome sequencing revealed 648 SNVs, most of which were C/G [ T/A substitutions.
To determine whether mutations found in our study were causally implicated in melanoma development, we queried the mutations against the cancer gene census. Overall, 25 genes (7 for AMs and 18 for NAMs) harboring SNVs were also in the cancer gene census. Five mutations in 4 genes (BRAF, NRAS, KDR, and PTPRB) overlapped with the top 20 mutations in malignant melanoma defined by the COSMIC (Catalogue of Somatic Mutations in Cancer) database. Missense mutations BRAF V600E and NRAS Q61R, which are wellknown driver mutations in melanoma, were observed in AM1 and AM2 subtypes. NAMs did not have BRAF and NRAS hotspot mutations. We found 228 copy number alterations (146 gains and 82 losses) with a median of 17 (range 10e24) for AMs and 42 (range 22e72) for NAMs. NAM genomes had significantly more copy number alterations than AMs (P ¼ .035). Copy number alteration profiles at the individual gene level are shown in Fig 1 .
Four genetic types of melanoma have been suggested by The Cancer Genome Atlas group. 4 AM1 is a BRAF subtype with hotspot mutations in BRAF, and AM2 is a RAS subtype with hotspot mutations in RAS. NAM1 and NAM3 have copy number losses in the NF1 gene that are considered to be associated with functional alteration of the NF1 gene. NAM2 and NAM4 are triple-wild subtype, without mutations in BRAF, RAS, or NF1. 4 Comprehensive genetic alterations in our samples according to pathways involved in melanoma pathogenesis are presented in Supplemental Table I (available at http://www.jaad.org).
Genomic alterations of CARD11; chromatinremodeling genes (ARID2, ARID1A, and ARID1B); and protein phosphatase genes (PTPRB and PTPRK ) were distinctive for NAM in this study. On the basis of these results, NAM should be considered genetically distinct from AM. In metastatic melanomas, adjuvant treatments for NAM should be approached differently from AM. 2 However, because of limited patient satisfaction data on these 2 options, we aimed to study any differences from the patient perspective.
This quality improvement project (institutional review board exemption obtained) surveyed consecutive patients (identified retrospectively) who had a linear repair performed during July-August 2016 at our institution. We collected demographic and procedural data, including internal and external sutures used and postoperative issues and complications. Wound care entailed either petroleum jelly or wound closure strips on the basis of patient preference. Patients were called 3-6 months after their repair to assess patient satisfaction of cosmetic outcomes, type of sutures placed, and future suture preference (Table I) .
In total, 134 patients were called, and 91 (52 men, 39 women) of 101 patients reached participated in the survey. Median age of participants was 75 (range 35-95) years. Thirty-four of 91 (37.4%) received external absorbable sutures (poliglecaprone-25 running subcuticular or fast-absorbing gut running continuous) and 57 of 91 (62.6%) received external NASs (polypropylene running continuous). Table II lists suture preference per cohort. Overall, there was no difference in patient satisfaction regarding suture type placed (NAS mean satisfaction 4.63/5 6 0.75, absorbable suture mean satisfaction 4.79/5 6 0.48; P ¼ .25) or cosmetic outcome (NAS mean satisfaction 4.27/5 6 0.99, absorbable suture mean satisfaction 4.56/5 6 0.72; P ¼ .14). There was no statistically significant difference among women (absorbable suture group, n ¼ 12, mean satisfaction 4.46/ 5 6 0.72; NAS group, n ¼ 27, mean satisfaction 4.02/5 6 1.18; P ¼ .24) or men (absorbable suture group, n ¼ 22, mean satisfaction 4.61/5 6 0.72; NAS group, n ¼ 30, mean satisfaction 4.50/5 6 0.73; P ¼ .59). There was also no difference in rates of postoperative complications and concerns (P ¼ .99).
Most (54.9%, 50/91) patients did not believe it was imperative that a medical professional evaluate every scar in the immediate postoperative period. However, only 43.6% (17/39) of women had this impression compared with 63.5% (33/52) of men surveyed. Most patients who received an absorbable suture (67.6%, 23/34) would prefer them in the future. In the NAS cohort, most (54.4%, 31/57) had no preference; 81.6% (31/38) of patients who preferred absorbable sutures cited patient convenience and the lack of a suture removal visit as reasoning.
These results indicate that absorbable sutures did not affect patient satisfaction. The majority reported either no preference or preference for absorbable sutures. NASs require a suture removal visit, which might inconvenience the patient due to lengthy distance of travel, advanced age, comorbid conditions, limited mobility, or work and family obligations. Absorbable sutures permit scheduling flexibility for the return visit, and postoperative visits after the immediate healing stage allows the surgeon to better assess repair outcomes, considering it might take weeks for inflammation to resolve and months for scars to mature. 3 Absorption is completed after 21-42 days for fast-absorbing gut and 91-119 days for poliglecaprone-25 sutures, although tensile strength is lost within 7 days and 21 days for fast-absorbing Supplemental 
